Investor Overview

Corporate Profile

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Stock Quote

All Recent News
Date Title  
04/08/21
Printer Friendly Version
04/06/21
Printer Friendly Version
03/02/21
Printer Friendly Version
02/23/21
Printer Friendly Version
National Recent News
Date Title  
04/08/21
Printer Friendly Version
04/06/21
Printer Friendly Version
03/02/21
Printer Friendly Version
02/23/21
Printer Friendly Version
International Recent News
Date Title  
08/13/19
Printer Friendly Version
08/28/18
Printer Friendly Version
06/05/18
Printer Friendly Version
04/25/17
Printer Friendly Version
Events
Date Title
04/27/21 4:30 PM EDT